M&A - AYTU BIOPHARMA, INC

Form Type: 8-K

Filing Date: 2025-06-06

Corporate Action: Acquisition

Type: New

Accession Number: 000143774925019718

Filing Summary: On June 5, 2025, Aytu BioPharma, Inc. announced an Exclusive Commercialization Agreement with Fabre-Kramer Holdings, Inc. for the commercialization of EXXUA™ (gepirone) extended release tablets, an FDA-approved treatment for Major Depressive Disorder (MDD). The agreement entails an upfront cash payment of $3 million, with additional $3 million payments contingent upon sales milestones. The company expects to launch EXXUA in Q4 2025, anticipating significant revenue potential in the $22 billion MDD market. The agreement includes various milestone payments and specific royalty structures based on product net sales. Termination clauses are included in case of mutual agreement or material breaches. A press release regarding the agreement was issued on June 6, 2025.